A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II).
Barbanti P, Aurilia C, Egeo G, Doretti A, d'Onofrio F, Scatena P, Rinalduzzi S, Vinciguerra L, Sansone M, Vecchio R, Drago V, Viticchi G, Bartolini M, Ranieri A, Bandettini di Poggio M, Baldisseri F, Mascarella D, Brusaferri F, Caputi L, Messina S, Autunno M, Valenza A, Orlando B, Distefano M, Borrello L, Pistoia F, Camarda C, Saporito G, Querzola G, Torelli P, Salerno A, Gragnani F, Petolicchio B, Carnevale A, Messina R, Filippi M, Tavani S, Fiorentini G, Bonassi S, Cevoli S, Mannocci A; Italian Migraine Registry (I-GRAINE) study group.
Barbanti P, et al. Among authors: doretti a.
J Neurol. 2025 May 7;272(6):382. doi: 10.1007/s00415-025-13095-z.
J Neurol. 2025.
PMID: 40332560
Free PMC article.